ASHLEY COLLINS: Open Payments
NPI 1164204376 · MIDLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$665 in 20 payments from 10 companies in 2025. Trend: 2023 $20 · 2024 $819 · 2025 $665
Food & beverage: $576Education: $89
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 6 | $191 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $105 |
| CSL Behring | 1 | $97 |
| AstraZeneca Pharmaceuticals LP | 3 | $80 |
| E.R. Squibb & Sons, L.L.C. | 2 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Merck Sharp & Dohme LLC | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $14 |
Products named: DUPIXENT, NEFFY, Andembry, TEZSPIRE, CAMZYOS, JARDIANCE, VERQUVO, AMVUTTRA.
Industry payments across TX — which companies pay providers there.
